Add Formweb to your mobile device
Search results for:
tocilizumab
tocilizumab
Brand names: Actemra, Tofidence, Tyenne
| Form | Strength | ANAN | ASMP | LACH | LALK | LOHH | LOLR | LOWC | SDSD | SESE | SFSF | Formulary Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SOLUTION, INTRAVENOUS | 20 mg/mL; aazg 20 mg/mL; bavi 80 mg/4mL; bavi 200 mg/10mL; bavi 400 mg/20mL | Restricted |
Last updated: Oct. 15, 2025
- Black Box Warning: Serious infections risk
- Therapeutic Interchange: Biosimilar and Reference Products Conversion List for Adults
- Do Not Tube-LALK
- Restricted: Tocilizumab is formulary, restricted to use in the outpatient setting. Restricted use in the inpatient setting for treatment of patients with specific indications (see comments).
Tocilizumab Executive Summary
Medications Approved for Automatic Therapeutic Interchange Dosage Conversion Guidelines
(Note: “Therapeutic Interchange” should be placed in the order comments)
Biosimilar and Reference Products Interchange List for Adults
Medication
Reference Drug or Biosimilar
Formulary Status
Automatic Therapeutic Interchange
Inpatient1
Outpatient
*New Starts/New Authorizations Only*
Actemra (tocilizumab)
Reference
Formulary, restricted to OP
(preferred) and inpatient use restricted to criteria3
Product selection at the discretion of each facility for restricted indications only3
Use Actemra unless third party payer requires other tocilizumab product
Tyenne (tocilizumab-aazg)
Avtozma (tocilizumab-anoh)
Tofidence (tocilizumab-bavi)
Biosimilars
Formulary, restricted to OP
(not preferred) and inpatient use restricted to criteria3
Interchange to Actemra unless third party payer requires other tocilizumab product
Actemra and Tyenne are the only tocilizumab products with FDA approval for cytokine release syndrome (chimeric antigen receptor T-cell therapy-associated). Actemra is the only tocilizumab product with FDA approval for systemic sclerosis (scleroderma)-associated interstitial lung disease (SSc-ILD).
3Inpatient tocilizumab use restricted to COVID-19 or oncology patients with cytokine release syndrome related to bi-specific T-cell engaging therapy; Chimeric antigen receptor T-cell therapy (CAR T-cell Therapy); or post allogeneic stem cell transplant.
***Tocilizumab (Actemra) is temporarily approved for use in cytokine storm related to COVID-19. Please reach out to Pharmacy Leadership for acquisition. See COVID-19 Treatment Recommendations for dosing.